Contact us

Your Cart Is Empty

Gilotrif (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

 
Gilotrif (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Summary

Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident cases of the disease will be major drivers of growth in the major markets.

Gilotrif is an irreversible inhibitor of the ErbB family of receptors, which include EGFR and HER2, and it has TKI activity against the wild-type as well as the mutant EGFR receptor. This distinguishes it from Tarceva and Iressa, which are reversible TKIs that only target the mutant receptor. Boehringer Ingelheim received FDA marketing approval for Gilotrif in July 2013 for the first-line treatment of EGFR-mutant NSCLC patients.

Scope

• Overview of NSCLC, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Gilotrif including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Gilotrif for the top nine countries from 2012 to 2022.
• Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, India and China.

Reasons To Buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for NSCLC
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of Gilotrif performance
• Obtain sales forecast for Gilotrif from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, India and China)

Purchase this Report

1-User PDF US$3,495.00
Site PDF US$6,990.00
Enterprise PDF
+ Free iPad!
US$10,485.00
Payment options
Get Free Email Updates

Questions about this report?
+1 646 513 4192 (US)
+31 20 486 1286 (EU)

Contact us by email
Jun 2013
GlobalData
71 pages

Global Market Research
ASDR-74906

Related Categories

Related Events